Aortic Stenosis and Dialysis: Is TAVR the Strategy of Choice?

Courtesy of Dr. Carlos Fava.

acceso carotideo taviTAVR has been shown beneficial in high and moderate risk patients, but there is a group of patients that require dialysis on account of kidney deterioration.  This comorbidity is due to bad cardiovascular evolution associated to diabetes, bleeding and thromboembolic events.

 

For some time, we have been using an aortic valve percutaneous replacement strategy in this group, but there is little evidence of its benefits compared against surgical replacement.

 

This study included 1025 patients: 328 (32%) received TAVR (69 patients via transapical access) and 697 surgical aortic valve replacement (SAVR).


Read also: Differences in Stroke between TAVR and SAVR in Intermediate Risk Patients.


TAVR patients were older (75.3 vs. 61.6 mean age, P<0.001) and higher comorbidities index, such as heart failure (16.2% vs. 7.5%, P<0.001), diabetes (28.4% vs. 22.5%, P 0.05) and chronic obstructive pulmonary disease (27.7% vs. 20.4% p0 0.05). Instead, those undergoing SAVR more often had coagulation disorders (41.6% vs. 28.4% p>0.05), and neurological compromise (10.9% vs. 6.7% p<0.05) and took more drugs (3% vs. 0.6% p<0.05).

 

Using propensity score, patient population was matched into 175 pairs.

 

In-hospital mortality was similar (8% for TAVR vs. 10.3% for SAVR p=0.58). Patients undergoing TAVR had shorter hospitalization (8 vs. 14 days p<0.001), lower hospital cost (U$S 276.488 vs. U$S 364.280 p =0.01), fewer in-hospital complications (60.6% vs. 76% p 0.003) higher home discharge (76% vs. 60.6% p 0.004), in addition to less need for transfusion and fewer breathing complications.

 

Conclusion

Regardless treatment mortality, severe aortic stenosis patients have higher in-hospital mortality. TAVR and SAVR presented similar in-hospital mortality but TAVR was associated to shorter hospitalization, lower hospitalization cost, less in-hospital complications and higher discharge.

 

Courtesy of Dr. Carlos Fava.

 

Original Title: In-hospital outcomes of transcatheter versus surgical aortic valve replacement in end stage renal disease.

Reference: Ahmad Alkhalil, et al. Cardiovasc Interv.  Catheter Cardiovasc Interv. 2018;92:757–765.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...